{"id":71395,"date":"2026-07-30T20:38:07","date_gmt":"2026-07-30T12:38:07","guid":{"rendered":"https:\/\/flcube.com\/?p=71395"},"modified":"2026-07-30T20:38:08","modified_gmt":"2026-07-30T12:38:08","slug":"microport-neuroscientifics-artemis-dream-intracranial-drug-eluting-stent-enters-nmpa-green-channel-as-chinas-first-targeted-release-self-expanding-system","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71395","title":{"rendered":"MicroPort NeuroScientific&#8217;s Artemis Dream Intracranial Drug-Eluting Stent Enters NMPA Green Channel as China&#8217;s First Targeted-Release Self-Expanding System"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>MicroPort NeuroScientific Corporation Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/2172:HKG\">HKG: 2172<\/a>) announced that its <strong>Artemis Dream (ChanJuan) self-expanding intracranial rapamycin-eluting stent system<\/strong> has been granted entry into China&#8217;s <strong>National Medical Products Administration (NMPA) innovative medical device special review procedure<\/strong> (Green Channel). Developed by subsidiary <strong>MicroPort NeuroScientific (Shanghai) Co., Ltd.<\/strong>, the Artemis Dream represents <strong>China&#8217;s first domestically developed targeted-drug-release self-expanding intracranial arterial stent<\/strong>, designed to address critical limitations in current neurovascular intervention technologies.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>Innovative Medical Device Special Review (Green Channel)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Artemis Dream (ChanJuan) self-expanding intracranial rapamycin-eluting stent system<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Intracranial arterial stenosis and vascular reconstruction<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>MicroPort NeuroScientific (Shanghai) Co., Ltd. (subsidiary of HKG: 2172)<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>First domestically developed targeted-drug-release self-expanding intracranial stent in China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-technology-profile-amp-clinical-innovation\" class=\"wp-block-heading\">Technology Profile &amp; Clinical Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Stent Architecture:<\/strong> <strong>Self-expanding design<\/strong> with optimized balance between <strong>mechanical support performance<\/strong> and <strong>metal coverage ratio<\/strong>, minimizing vascular injury risk during deployment and long-term implantation<\/li>\n\n\n\n<li><strong>Drug Delivery System:<\/strong> <strong>Directional drug release<\/strong> technology that delivers <strong>rapamycin exclusively toward the vessel wall<\/strong>, avoiding systemic exposure and maximizing local therapeutic effect<\/li>\n\n\n\n<li><strong>Mechanism of Action:<\/strong> Rapamycin inhibits <strong>intimal hyperplasia<\/strong> while promoting <strong>accelerated endothelialization<\/strong>, addressing the dual challenges of restenosis prevention and vascular healing<\/li>\n\n\n\n<li><strong>Clinical Benefit:<\/strong> Potential to <strong>significantly shorten dual antiplatelet therapy (DAPT) duration<\/strong> post-procedure, reducing bleeding complications and improving patient compliance<\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> Fully domestic R&amp;D and production capabilities, supporting China&#8217;s strategic goal of <strong>medical device self-reliance<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-unmet-need\" class=\"wp-block-heading\">Market Context &amp; Unmet Need<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Intracranial atherosclerotic disease<\/strong> affects approximately <strong>10-15% of stroke patients<\/strong> in Asia, with higher prevalence rates compared to Western populations. Current treatment options include <strong>medical management, angioplasty, and bare-metal stenting<\/strong>, but all are associated with significant limitations including <strong>high restenosis rates (20-30%)<\/strong> and <strong>extended DAPT requirements (6-12 months)<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>global neurovascular devices market<\/strong> is valued at <strong>$3.2 billion annually<\/strong> and growing at <strong>8.5% CAGR<\/strong>, driven by aging populations and increasing stroke incidence. However, <strong>drug-eluting intracranial stents<\/strong> remain underdeveloped compared to coronary applications, creating substantial opportunity for innovative solutions like Artemis Dream.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Key clinical advantages over existing technologies:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Reduced restenosis risk<\/strong> through targeted anti-proliferative drug delivery<\/li>\n\n\n\n<li><strong>Enhanced safety profile<\/strong> via shortened DAPT requirements<\/li>\n\n\n\n<li><strong>Improved vessel compatibility<\/strong> through optimized mechanical design<\/li>\n\n\n\n<li><strong>Faster endothelial healing<\/strong> promoting long-term vascular stability<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For MicroPort NeuroScientific:<\/strong> Establishes leadership position in <strong>next-generation neurovascular interventions<\/strong> and creates potential for <strong>global expansion<\/strong> beyond Chinese market<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> First-mover advantage in <strong>targeted-release intracranial stent segment<\/strong> with significant differentiation from bare-metal and non-targeted drug-eluting alternatives<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> <strong>Green Channel designation<\/strong> accelerates approval timeline by <strong>6-12 months<\/strong> compared to standard review process<\/li>\n\n\n\n<li><strong>Commercial Strategy:<\/strong> Leverage MicroPort&#8217;s established <strong>neurovascular sales force<\/strong> and hospital relationships for rapid market adoption<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-next-steps\" class=\"wp-block-heading\">Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Trial Initiation:<\/strong> Pivotal trial expected to commence in Q4 2026 with primary endpoints focused on <strong>safety, efficacy, and DAPT duration reduction<\/strong><\/li>\n\n\n\n<li><strong>Regulatory Timeline:<\/strong> Target <strong>NMPA marketing approval by Q2 2028<\/strong> leveraging Green Channel benefits<\/li>\n\n\n\n<li><strong>International Strategy:<\/strong> Prepare <strong>CE Mark and FDA submissions<\/strong> following successful Chinese approval<\/li>\n\n\n\n<li><strong>Manufacturing Scale-up:<\/strong> Expand production capacity to meet anticipated commercial demand<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development timelines, and commercial opportunities. Actual results may differ due to risks including clinical trial outcomes, regulatory requirements, competitive developments, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026073000074_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026073000074_c.\"><\/object><a id=\"wp-block-file--media-0c0116fc-56be-46ad-880e-c1d163552f27\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026073000074_c.pdf\">2026073000074_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026073000074_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-0c0116fc-56be-46ad-880e-c1d163552f27\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MicroPort NeuroScientific Corporation Limited (HKG: 2172) announced that its Artemis Dream (ChanJuan) self-expanding intracranial rapamycin-eluting&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,22],"tags":[1462,4873],"class_list":["post-71395","post","type-post","status-publish","format-standard","hentry","category-company","category-medical-device","tag-hkg-2172","tag-microport-neuroscientific"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>MicroPort NeuroScientific&#039;s Artemis Dream Intracranial Drug-Eluting Stent Enters NMPA Green Channel as China&#039;s First Targeted-Release Self-Expanding System - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"MicroPort NeuroScientific Corporation Limited (HKG: 2172) announced that its Artemis Dream (ChanJuan) self-expanding intracranial rapamycin-eluting stent system has been granted entry into China&#039;s National Medical Products Administration (NMPA) innovative medical device special review procedure (Green Channel). Developed by subsidiary MicroPort NeuroScientific (Shanghai) Co., Ltd., the Artemis Dream represents China&#039;s first domestically developed targeted-drug-release self-expanding intracranial arterial stent, designed to address critical limitations in current neurovascular intervention technologies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71395\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MicroPort NeuroScientific&#039;s Artemis Dream Intracranial Drug-Eluting Stent Enters NMPA Green Channel as China&#039;s First Targeted-Release Self-Expanding System\" \/>\n<meta property=\"og:description\" content=\"MicroPort NeuroScientific Corporation Limited (HKG: 2172) announced that its Artemis Dream (ChanJuan) self-expanding intracranial rapamycin-eluting stent system has been granted entry into China&#039;s National Medical Products Administration (NMPA) innovative medical device special review procedure (Green Channel). Developed by subsidiary MicroPort NeuroScientific (Shanghai) Co., Ltd., the Artemis Dream represents China&#039;s first domestically developed targeted-drug-release self-expanding intracranial arterial stent, designed to address critical limitations in current neurovascular intervention technologies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71395\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-30T12:38:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-30T12:38:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71395#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71395\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"MicroPort NeuroScientific&#8217;s Artemis Dream Intracranial Drug-Eluting Stent Enters NMPA Green Channel as China&#8217;s First Targeted-Release Self-Expanding System\",\"datePublished\":\"2026-07-30T12:38:07+00:00\",\"dateModified\":\"2026-07-30T12:38:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71395\"},\"wordCount\":544,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 2172\",\"MicroPort NeuroScientific\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71395#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71395\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71395\",\"name\":\"MicroPort NeuroScientific's Artemis Dream Intracranial Drug-Eluting Stent Enters NMPA Green Channel as China's First Targeted-Release Self-Expanding System - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-30T12:38:07+00:00\",\"dateModified\":\"2026-07-30T12:38:08+00:00\",\"description\":\"MicroPort NeuroScientific Corporation Limited (HKG: 2172) announced that its Artemis Dream (ChanJuan) self-expanding intracranial rapamycin-eluting stent system has been granted entry into China's National Medical Products Administration (NMPA) innovative medical device special review procedure (Green Channel). Developed by subsidiary MicroPort NeuroScientific (Shanghai) Co., Ltd., the Artemis Dream represents China's first domestically developed targeted-drug-release self-expanding intracranial arterial stent, designed to address critical limitations in current neurovascular intervention technologies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71395#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71395\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71395#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MicroPort NeuroScientific&#8217;s Artemis Dream Intracranial Drug-Eluting Stent Enters NMPA Green Channel as China&#8217;s First Targeted-Release Self-Expanding System\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MicroPort NeuroScientific's Artemis Dream Intracranial Drug-Eluting Stent Enters NMPA Green Channel as China's First Targeted-Release Self-Expanding System - Insight, China&#039;s Pharmaceutical Industry","description":"MicroPort NeuroScientific Corporation Limited (HKG: 2172) announced that its Artemis Dream (ChanJuan) self-expanding intracranial rapamycin-eluting stent system has been granted entry into China's National Medical Products Administration (NMPA) innovative medical device special review procedure (Green Channel). Developed by subsidiary MicroPort NeuroScientific (Shanghai) Co., Ltd., the Artemis Dream represents China's first domestically developed targeted-drug-release self-expanding intracranial arterial stent, designed to address critical limitations in current neurovascular intervention technologies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71395","og_locale":"en_US","og_type":"article","og_title":"MicroPort NeuroScientific's Artemis Dream Intracranial Drug-Eluting Stent Enters NMPA Green Channel as China's First Targeted-Release Self-Expanding System","og_description":"MicroPort NeuroScientific Corporation Limited (HKG: 2172) announced that its Artemis Dream (ChanJuan) self-expanding intracranial rapamycin-eluting stent system has been granted entry into China's National Medical Products Administration (NMPA) innovative medical device special review procedure (Green Channel). Developed by subsidiary MicroPort NeuroScientific (Shanghai) Co., Ltd., the Artemis Dream represents China's first domestically developed targeted-drug-release self-expanding intracranial arterial stent, designed to address critical limitations in current neurovascular intervention technologies.","og_url":"https:\/\/flcube.com\/?p=71395","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-30T12:38:07+00:00","article_modified_time":"2026-07-30T12:38:08+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71395#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71395"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"MicroPort NeuroScientific&#8217;s Artemis Dream Intracranial Drug-Eluting Stent Enters NMPA Green Channel as China&#8217;s First Targeted-Release Self-Expanding System","datePublished":"2026-07-30T12:38:07+00:00","dateModified":"2026-07-30T12:38:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71395"},"wordCount":544,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 2172","MicroPort NeuroScientific"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71395#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71395","url":"https:\/\/flcube.com\/?p=71395","name":"MicroPort NeuroScientific's Artemis Dream Intracranial Drug-Eluting Stent Enters NMPA Green Channel as China's First Targeted-Release Self-Expanding System - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-30T12:38:07+00:00","dateModified":"2026-07-30T12:38:08+00:00","description":"MicroPort NeuroScientific Corporation Limited (HKG: 2172) announced that its Artemis Dream (ChanJuan) self-expanding intracranial rapamycin-eluting stent system has been granted entry into China's National Medical Products Administration (NMPA) innovative medical device special review procedure (Green Channel). Developed by subsidiary MicroPort NeuroScientific (Shanghai) Co., Ltd., the Artemis Dream represents China's first domestically developed targeted-drug-release self-expanding intracranial arterial stent, designed to address critical limitations in current neurovascular intervention technologies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71395#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71395"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71395#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"MicroPort NeuroScientific&#8217;s Artemis Dream Intracranial Drug-Eluting Stent Enters NMPA Green Channel as China&#8217;s First Targeted-Release Self-Expanding System"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71395","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71395"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71395\/revisions"}],"predecessor-version":[{"id":71397,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71395\/revisions\/71397"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71395"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71395"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71395"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}